本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-027 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 第四届监事会第三次会议决议公告 漱玉平民大药房连锁股份有限公司（以下简称"公司"）第四届监事会第三次会议于 2025 年 4 月 27 日在公司会议室以现场方式召开。会议通知及会议资料已于 2025 年 4 月 16 日以 书面、电子邮件等方式送达各位监事。本次会议由监事会主席孟鹏女士召集并主持，会议 应到监事 3 人，实到监事 3 人，董事会秘书列席了本次会议。本次会议召开符合《中华人 民共和国公司法》（以下简称"《公司法》"）及《公司章程》等有关规定。 二、监事会会议审议情况 1、审议通过《关于公司<2024 年度监事会工作报告>的议案》 2024 年度，监事会严格按照《公司法》《证券法》等法律法规及《公司章程》等规章制 度的规定，依法履行监事会职责。本着恪尽职守、勤 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-026 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 第四届董事会第五次会议决议公告 漱玉平民大药房连锁股份有限公司（以下简称"公司"）第四届董事会第五次会议于 2025 年 4 月 27 日在公司会议室以现场结合通讯表决的方式召开。会议通知已于 2025 年 4 月 16 日以书面、电子邮件等方式送达各位董事，会议应到董事 9 人，实到董事 9 人，其中董事 杨策先生以通讯表决方式出席。公司监事和高级管理人员列席了本次会议。会议由公司董 事长李文杰先生主持，本次会议召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 及《漱玉平民大药房连锁股份有限公司章程》（以下简称"《公司章程》"）等有关规定。 二、董事会会议审议情况 1、审议通过《关于公司<2024 年度董事会工作报告>的议案》 2024 年度，董事会严格按照《公司法》《证券法》等法律法规及《公司章程》等规章制 度的规定，依法履行董事会的职责，恪尽职守、积极有效地行使职权，认真贯彻落 ...

漱玉平民大药房连锁股份有限公司第四届董事会 独立董事专门会议 2025 年第二次会议决议 漱玉平民大药房连锁股份有限公司（以下简称"公司"）第四届董事会独立 董事专门会议 2025 年第二次会议于 2025 年 4 月 27 日在公司会议室以现场方式 召开。会议通知已于 2025 年 4 月 16 日以书面、电子邮件等方式送达各位独立董 事，会议应到独立董事 3 人，实到独立董事 3 人。经过半数独立董事推举，独立 董事晏莉女士召集并主持本次会议，本次会议召开符合《中华人民共和国公司法》 《上市公司独立董事管理办法》及《公司章程》等有关规定。 与会董事签字： 根据公司实际经营及业务发展需要，公司及子公司预计 2025 年度将与关联 方发生日常关联交易总额度不超过 10,148.00 万元。 经审核，我们认为：2025 年度公司与关联方的关联交易预计额度系公司日 常经营需要，公司关联交易公平、公正，交易事项符合市场经营规则，交易定价 公允。2024 年度日常关联交易实际发生金额与预计金额存在差异，主要是公司 2024 年度预计该关联交易的总金额是双方当年合作可能发生的金额，实际发生 额是按照双方实际业务合作进度 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-028 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 项目 2024 年度 2023 年度 2022 年度 现金分红总额（元） 0.00 20,117,579.05 46,614,100.00 回购注销总额（元） 0.00 0.00 0.00 归属于上市公司股东的净利润（元） -188,810,298.33 133,057,978.40 229,430,842.20 1、公司 2024 年度不派发现金红利，不触及其他风险警示情形 | 研发投入（元） | 0.00 | 0.00 | 51,059.81 | | --- | --- | --- | --- | | 营业收入（元） | 9,570,371,411.51 | 9,191,014,414.62 | 7,822,931,715.52 | | 合并报表本年度末累计未分配利润（元） | | 631,753,170.89 | | | 母公司报表本年度末累计未分配利润 | | 462,152,400. ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,378,617,267.98, a decrease of 2.48% compared to the same period last year[4] - Net profit attributable to shareholders increased by 143.85% to ¥25,623,877.14, driven by cost control measures and operational efficiency improvements[10] - Basic and diluted earnings per share both doubled to ¥0.06, reflecting the significant increase in net profit[10] - Net profit for the quarter reached CNY 22,247,586.65, representing a significant increase of 95.7% from CNY 11,377,582.93 in the same period last year[34] - The total comprehensive income for the current period is CNY 22,247,586.65, compared to CNY 11,377,582.93 in the previous period, reflecting a significant increase[36] - The comprehensive income attributable to the parent company's owners is CNY 25,623,877.14, up from CNY 10,508,208.55 in the previous period[36] Cash Flow - The net cash flow from operating activities rose by 17.52% to ¥88,358,510.08, indicating improved cash generation capabilities[4] - Net cash flow from operating activities is CNY 88,358,510.08, an increase from CNY 75,184,147.94 in the previous period[38] - Cash inflow from operating activities totaled CNY 2,540,858,188.81, down from CNY 2,701,517,754.85 in the previous period, representing a decrease of approximately 5.95%[38] - Cash outflow from operating activities decreased to CNY 2,452,499,678.73 from CNY 2,626,333,606.91, a reduction of about 6.61%[38] - Net cash flow from investing activities is CNY -204,364,524.68, compared to CNY 19,113,969.62 in the previous period, indicating a significant decline[41] - Cash inflow from financing activities is CNY 570,415,261.18, compared to CNY 522,642,916.67 in the previous period, showing an increase of approximately 9.13%[41] - The ending cash and cash equivalents balance is CNY 735,247,114.81, down from CNY 946,508,791.12 in the previous period, reflecting a decrease of about 22.29%[41] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,416,827,492.31, up 1.55% from the previous year[7] - The company's total assets as of March 31, 2025, were CNY 9,416,827,492.31, up from CNY 9,273,192,681.97 at the beginning of the period, indicating a growth of 1.5%[30] - Current assets totaled CNY 5,364,768,111.14, slightly increasing from CNY 5,321,094,993.28, reflecting a growth of 0.8%[28] - Non-current assets increased to CNY 4,052,059,381.17 from CNY 3,952,097,688.69, marking a growth of 2.5%[29] - Total liabilities rose to CNY 7,266,421,717.98, compared to CNY 7,148,122,388.98, an increase of 1.7%[30] - The company's equity attributable to shareholders increased to CNY 2,067,777,882.27 from CNY 2,040,366,110.44, reflecting a growth of 1.4%[31] Operational Efficiency - The company reported a 95.30% increase in other non-current assets, totaling ¥294,032,242.95, primarily due to increased prepayments for acquisitions[12] - The company implemented cost reduction measures, resulting in an improvement in expense-to-sales ratio by 1.81% year-on-year, with a net profit impact of approximately RMB 7.4 million due to changes in accounting estimates[22] - The gross profit margin decreased by 1.43% year-on-year due to changes in consumer purchasing behavior and increased compliance costs[22] - The company continues to optimize loss-making stores, positively impacting overall profitability[22] - The company reported a significant reduction in selling expenses, which decreased to CNY 467,997,957.92 from CNY 523,927,303.51, a reduction of approximately 10.7%[35] Store Operations - As of March 31, 2025, the company operated a total of 8,916 stores across several provinces, including 4,353 direct-operated stores and 4,563 franchise stores[23] - The company closed 86 stores during the reporting period, resulting in a total of 4,353 direct-operated stores by the end of Q1 2025[25] - The company plans to continue optimizing store operations and enhancing digital tools to further improve profitability in the upcoming quarters[10] - The company is focused on a direct chain marketing model and steady regional expansion strategy[23] Future Plans - The company plans to expand its product offerings in health products, healthcare, medical devices, and beauty products to meet consumer demand[23] - The company has not adjusted the conversion price of its convertible bonds despite triggering conditions for downward adjustment, maintaining the current price of RMB 12.71 per share[27] Investment Performance - The company’s investment income decreased by 164.63% to -¥313,434.23, mainly due to the absence of dividends from other non-current financial assets[12] - The company’s investment income showed a loss of CNY 313,434.23, compared to a gain of CNY 484,965.34 in the previous period, indicating a decline in investment performance[35] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,977, indicating a stable shareholder base[14] - The company has a share repurchase account holding 2,988,788 shares, representing 0.74% of the total share capital[16] Audit Status - The company has not undergone an audit for the first quarter report[42]

Financial Performance - The company's overall revenue growth has slowed, with a year-on-year decline of 2.43% in sales proportion of traditional advantage categories such as health foods and health devices[5]. - The overall gross margin decreased by 2.96% year-on-year due to increased operational costs and intensified competition in the pharmaceutical retail industry[5]. - The company recorded a goodwill impairment provision of RMB 48.88 million during the reporting period[9]. - The expense-to-sales ratio increased by 0.57% year-on-year, despite efforts to implement cost reduction and efficiency improvement measures[7]. - The company will not distribute cash dividends or issue bonus shares for the current fiscal year[12]. - The company's operating revenue for 2024 was CNY 9,570,371,411.51, representing a 4.13% increase compared to CNY 9,191,014,414.62 in 2023[26]. - The net profit attributable to shareholders for 2024 was a loss of CNY 188,810,298.33, a decrease of 241.90% from a profit of CNY 133,057,978.40 in 2023[26]. - The cash flow from operating activities for 2024 was CNY 489,316,905.89, which is a significant increase of 242.40% compared to CNY 142,908,920.66 in 2023[26]. - The total assets at the end of 2024 were CNY 9,273,192,681.97, a slight decrease of 0.65% from CNY 9,333,676,406.45 at the end of 2023[26]. - The company reported a basic earnings per share of -CNY 0.47 for 2024, down 242.42% from CNY 0.33 in 2023[26]. - The company experienced a significant decline in net profit after deducting non-recurring gains and losses, reporting a loss of CNY 197,922,310.83 in 2024 compared to a profit of CNY 126,881,608.02 in 2023, a decrease of 255.99%[26]. - The weighted average return on equity for 2024 was -9.36%, down from 6.28% in 2023, indicating a significant decline in profitability[26]. Market and Competitive Landscape - The retail pharmacy market in China saw a total sales scale of CNY 528.2 billion in 2024, a decline of 2.2% year-on-year[37]. - The pharmaceutical market within retail pharmacies accounted for 82.8% of the total market, with a growth of 0.3% year-on-year[37]. - The company ranked 8th in the "2022-2023 Annual China Chain Drugstore Top 50" list[41]. - Increased market competition is a concern, prompting the company to adopt a strategy of new store openings, acquisitions, and partnerships to strengthen its market position[125]. Operational Strategies - The company plans to optimize resource allocation and reduce logistics costs through warehouse consolidation and flexible procurement strategies[7]. - The company aims to deepen its presence in county markets and explore blank areas within the province through franchise and distribution business development[7]. - The company will continue to track national pharmaceutical policy dynamics and adjust its business strategies accordingly[6]. - The company has completed the layout of provincial and regional distribution centers in several provinces, including Shandong and Heilongjiang, to enhance market expansion[7]. - The company has established 11 logistics distribution centers with a total storage area exceeding 150,000 square meters, ensuring efficient product delivery across multiple provinces[60]. Store and Product Development - The company expanded its store network to 9,035 locations, adding 1,698 new stores during the reporting period[48]. - The number of direct-operated stores reached 4,438, with 57 new stores opened and 395 acquired[48]. - The company is focusing on diversifying its product matrix to meet the evolving health needs of consumers[44]. - The company has streamlined its self-owned product SKU from 878 to 704, improving operational efficiency and reducing inventory turnover risk[58]. - The company has developed a diverse product range, focusing on traditional Chinese medicine and health beauty industries, to meet various consumer demands[72]. Financial Management and Investments - The company has completed significant equity investments totaling ¥400,230,000.00 during the reporting period[103]. - The company has established a comprehensive internal control system covering various operational aspects, including finance and legal affairs[184]. - The company has implemented a performance evaluation mechanism for incentive plan participants based on individual performance metrics[182]. - The company has committed to various investment projects, including a modern logistics project with a total investment of RMB 28,000 million, which is currently not applicable for use[109]. Human Resources and Governance - The company has established a comprehensive human resource management system, enhancing training and performance management across the organization[74]. - The company has a complete corporate governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring independent operation[143]. - The company has a diverse management team with backgrounds in various fields, including pharmacy, accounting, and business management[150][155]. - The company has implemented a multi-dimensional incentive mechanism, including individual, team, and organizational incentives, to enhance talent value contribution[170]. Social Responsibility and Community Engagement - The company actively participated in social responsibility initiatives, donating approximately CNY 28.7 million to support special groups and families in need in 2024[192]. - A total of 30 health outreach events were conducted in 2024, reaching over 3,000 participants, focusing on early prevention of common diseases[193]. - The company organized 30 large community cultural festivals in 2024, engaging over 300,000 community residents to promote health awareness[193]. - In 2024, the company launched the "Light of Life" public welfare project, aiming to train at least 70,000 citizens in first aid knowledge through over 100 training sessions[194]. Shareholder Relations and Commitments - The controlling shareholder and actual controller, Li Wenjie, committed to holding all shares for 36 months post-IPO without transferring or entrusting management to others[199]. - The company commits to maintaining independence in operations, finance, and business despite the controlling shareholder's influence[200]. - The controlling shareholder promises not to engage in competitive business activities with the issuer or its subsidiaries[200]. - The company will publicly disclose any violations of share reduction intentions and apologize to shareholders and the public[199].

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-025 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日召开第 四届董事会第三次会议，于 2025 年 2 月 6 日召开 2025 年第一次临时股东大会，审议通过 了《关于 2025 年度公司及子公司向银行等机构申请综合授信额度及提供担保的议案》，同 意公司及子公司 2025 年度对合并报表范围内各级子公司提供的担保额度为人民币 167,011.00 万元。其中公司向全资子公司东营益生堂药业连锁有限公司（以下简称"东营 益生堂"）提供不超过 15,500 万元的担保额度。担保额度有效期自 2025 年第一次临时股 东大会审议通过之日起十二个月。具体内容详见公司于 2025 年 1 月 22 日和 2025 年 2 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 2 月 21 日和 2025 年 3 月 10 日召开第四届董事会第四次会议和 2025 年第二次临时股东大会审议通过了《关于续 聘会计师事务所的议案》，续聘天职国际会计师事务所（特殊普通合伙）（以下简称"天职国 际"）为公司 2024 年度财务报表和内部控制审计机构。具体内容详见公司于 2025 年 2 月 22 日和 2025 年 3 月 10 日披露在巨潮资讯网的《关于拟续聘会计师事务所的公告》《2025 年第二次临时股东大会决议公告》。 近日，公司收到天职国际出具的《关于变更漱玉平民大药房连锁股份有限公司 2024 年 度签字注册会计师的函》，现将有关情况公告如下： 一、签字注册会计师变更情况 天职国际作为公司聘任的 2024 年年度审计机构及内控审计机构，其原委派签字注册会 计师周春阳、王治宾、陈函担任公司 2024 年度审计业务签字注册会计师。由于人员变动， 现委派周春阳、张辰完成公司 2024 年度财务报表审计及内控审计的相关工作 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-023 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于 2025 年第一季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、漱玉转债（债券代码：123172）转股期限为 2023 年 6 月 21 日至 2028 年 12 月 14 日，最新有效的转股价格为人民币 14.95 元/股。 2、2025 年第一季度，共有 6 张"漱玉转债"完成转股（票面金额共计 0.06 万元人民 币），合计转成 40 股"漱玉平民"股票（股票代码：301017）；截至 2025 年 3 月 31 日， 合计共有 1,929 张"漱玉转债"完成转股（票面金额共计 19.29 万元人民币），合计转成 12,766 股"漱玉平民"股票（股票代码：301017）。 3、截至 2025 年第一季度末，漱玉平民大药房连锁股份有限公司（以下简称"公司"） 剩余可转换公司债券（以 ...

二、担保进展情况 近日，滨州漱玉向上海浦东发展银行股份有限公司济南分行（以下简称"浦发银行济 南分行"）申请人民币1,000万元的授信业务，公司为滨州漱玉的本次授信业务提供连带 责任保证。 上述担保事项在预计的担保额度范围内，无需另行召开董事会及股东大会审议。 本次提供担保前，公司为滨州漱玉提供的担保余额为0万元，本次提供担保后担保余额 为1,000万元，剩余可用担保额度为0万元。 本次担保提供后，扣除尚在有效期内的担保余额（包括：公司为漱玉医药物流（山 | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-022 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日召开第 四届董事会第三次会议，于 2025 年 2 月 6 日召开 2025 年第一次临时股东大会，审议通 ...